We introduced genome‐wide and kinome‐wide CRISPR libraries in HNSCC cell line models resistant to EGFR inhibition and conducted screens to identify genetic knockouts that enhance sensitivity to gefitinib or erlotinib. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.